Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098172 | 1.00 | HPGDS (0.58) | HPGDSCHRNA7CXCR4DPP4DPP7 | |
| SCHEMBL6099360 | 0.94 | HPGDS (0.59) | HPGDSCHRNA7CXCR4DPP4DPP7 | |
| SCHEMBL6100380 | 0.86 | HTR3A (0.67) | CHRNA7HTR3A | |
| SCHEMBL6100386 | 0.86 | HTR3A (0.67) | CHRNA7HTR3A | |
| SCHEMBL6098257 | 0.82 | CHRNA7 (0.68) | CHRNA7 | |
| SCHEMBL6098251 | 0.82 | CHRNA7 (0.68) | CHRNA7 | |
| SCHEMBL6101321 | 0.81 | HTR3A (0.66) | HPGDSCHRNA7CXCR4HTR3ACHRNB2 | |
| SCHEMBL843822 | 0.81 | CHRNA7 (0.65) | HPGDSCHRNA7HTR3A | |
| SCHEMBL843075 | 0.81 | CHRNA7 (0.72) | HPGDSCHRNA7HTR3A | |
| SCHEMBL842630 | 0.81 | CHRNA7 (0.72) | HPGDSCHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HPGDS 1600/4885CHRNA7 1836/4885CXCR4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.